EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chetomin, a SARS-CoV-2 3C-like Protease (3CLpro) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis

Mahmoud A A Ibrahim iD, Alaa H M Abdelrahman iD, Dina E M Mohamed, Khlood A A Abdeljawaad iD, Mohamed Ahmed Naeem, Gamal A Gabr iD, Ahmed M Shawky iD, Mahmoud E S Soliman, Peter A Sidhom iD, Paul W Paré iD, Mohamed-Elamir F Hegazy iD

Viruses · 2023

DOI: 10.3390/v15010250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Mahmoud A A Ibrahim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Development Fund, Umm al-Qura University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of the Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 6 million deaths. The 3C-like protease (3CLpro) enzyme of the SARS-CoV-2 virus is an attractive druggable target for exploring therapeutic drug candidates to combat COVID-19 due to its key function in viral replication. Marine natural products (MNPs) have attracted considerable attention as alternative sources of antiviral drug candidates. In looking for potential 3CLpro inhibitors, the MNP database (>14,000 molecules) was virtually screened against 3CLpro with the assistance of molecular docking computations. The performance of AutoDock and OEDocking software in anticipating the ligand-3CLpro binding mode was first validated according to the available experimental data. Based on the docking scores, the most potent MNPs were further subjected to molecular dynamics (MD) simulations, and the binding affinities of those molecules were computed using the MM-GBSA approach. According to MM-GBSA//200 ns MD simulations, chetomin (UMHMNP1403367) exhibited a higher binding affinity against 3CLpro than XF7, with ΔGbinding values of −55.5 and −43.7 kcal/mol, respectively. The steadiness and tightness of chetomin with 3CLpro were evaluated, revealing the high stabilization of chetomin (UMHMNP1403367) inside the binding pocket of 3CLpro throughout 200 ns MD simulations. The physicochemical and pharmacokinetic features of chetomin were also predicted, and the oral bioavailability of chetomin was demonstrated. Furthermore, the potentiality of chetomin analogues –namely, chetomin A-D– as 3CLpro inhibitors was investigated. These results warrant further in vivo and in vitro assays of chetomin (UMHMNP1403367) as a promising anti-COVID-19 drug candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansMolecular Dynamics SimulationMolecular Docking SimulationPeptide HydrolasesViral Nonstructural ProteinsCysteine EndopeptidasesProtease InhibitorsAntiviral AgentsDisulfidesIndole Alkaloids

Stichwörter der Autor:innen

ADMET studyMD simulationSARS-CoV-2 3CLprodocking computationsmarine natural products (MNPs)

Substanzen

Peptide HydrolasesViral Nonstructural ProteinsCysteine EndopeptidasesProtease InhibitorsAntiviral AgentschetominDisulfidesIndole Alkaloids

Autor:innen und Institutionen

  • Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt.
  • School of Health Sciences, University of KwaZulu-Natal, Westville, Durban 4000, South Africa.
  • Ain Shams University Specialized Hospital, Ain Shams University, Cairo 11588, Egypt.
  • Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
  • Agricultural Genetic Engineering Research Institute (AGERI), Agricultural Research Center, Giza 12619, Egypt.
  • Science and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia.

ORCID-Profile: Mahmoud A A Ibrahim, Alaa H M Abdelrahman, Khlood A A Abdeljawaad, Gamal A Gabr, Ahmed M Shawky, Peter A Sidhom, Paul W Paré, Mohamed-Elamir F Hegazy

Förderung

  • Science and Technology Development Fund
  • Umm al-Qura University

Zitieren

APA

Ibrahim, M. A. A., Abdelrahman, A. H. M., Mohamed, D. E. M., Abdeljawaad, K. A. A., Naeem, M. A., Gabr, G. A., Shawky, A. M., Soliman, M. E. S., Sidhom, P. A., Paré, P. W., & Hegazy, M. F. (2023). Chetomin, a SARS-CoV-2 3C-like Protease (3CLpro) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis. Viruses. https://doi.org/10.3390/v15010250

Vancouver

Ibrahim MAA, Abdelrahman AHM, Mohamed DEM, Abdeljawaad KAA, Naeem MA, Gabr GA, et al. Chetomin, a SARS-CoV-2 3C-like Protease (3CLpro) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis. Viruses. 2023. doi:10.3390/v15010250

BibTeX
@article{Ibrahim2023,
  author = {Ibrahim, Mahmoud A A and Abdelrahman, Alaa H M and Mohamed, Dina E M and Abdeljawaad, Khlood A A and Naeem, Mohamed Ahmed and Gabr, Gamal A and Shawky, Ahmed M and Soliman, Mahmoud E S and Sidhom, Peter A and Paré, Paul W and Hegazy, Mohamed-Elamir F},
  title = {Chetomin, a SARS-CoV-2 3C-like Protease (3CLpro) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15010250}
}
Kostenlos starten →